0:00
Hello, I'm Professor John Cooke.
I'm the founding Director of the
Center for RNA Therapeutics here
at Houston Methodist
Research Institute
in the Texas Medical Center.
Today's Henry Stewart
Talk is going to
be about "RNA Therapeutics, Clinical
Applications, and Methods of Delivery".
0:22
Before I begin, let me
disclose my conflicts.
I am an inventor on RNA
technologies assigned
to Stanford University and to
Houston Methodist Hospital.
I'm the founder of
ChromeX Bio which is
developing mRNA
telomerase therapies.
I'm a member of the Scientific Advisory
Board of Humann, Cordex Bio,and JanOne.
And I'm the principal
investigator on
sponsored research agreements
with Avita and VGXI.
0:50
We're going to be talking
today about messenger RNA,
but just a slide to remind us
of the diversity of RNA species.
In addition to messenger
RNA, there's transfer RNA,
ribosomal RNA, microRNA, long
non-coding RNA, et cetera.
That diversity of
RNA also represents
some great opportunities for
therapeutic development.
1:13
Indeed, there is a diversity of
RNA drugs becoming available
and becoming
clinically approved.
Most of the approved
drugs at the moment are
antisense oligonucleotides and
interference RNA products.
But messenger RNA, of course,
is also coming down the pike.
1:32
We know that messenger
RNA works because it
is essentially
biological software,
the cellular instructions
to make any protein.
The idea for
therapeutic RNA is that
one gets it into the
cell of interest
and that messenger RNA
in the cytoplasm gets
translated into therapeutic
proteins by the ribosomes.
